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Peroxisome proliferator-activated receptor-γ coactivator-1α in
muscle links metabolism to inflammation
Abstract
1. In higher eukaryotes, metabolism and immunity are tightly coupled. However, whereas evolutionary,
a compromised immune response due to undernourishment has been the predominant problem, the
inflammatory response to obesity and other life style-associated diseases gained in relevance in Western
societies in the last hundred years. 2. Traditionally, fat tissue has been considered as the major source of
proinflammatory secreted factors in these pathologies. In recent years however, the contribution of other
tissues to a disease-causing chronic inflammation has been increasingly appreciated. 3. The peroxisome
proliferator-activated receptor γ coactivator 1α (PGC-1α) is one of the key regulatory factors in the
active skeletal muscle. Aberrant expression of PGC-1α in inactive muscle fibers could link a sedentary
life style, persistent systemic inflammation and the higher risk for many chronic diseases. Modulation of
PGC-1α activity in skeletal muscle might accordingly have a broad therapeutic effect. Here, recent
advances in the understanding of the role of muscle PGC-1α in health and disease are reviewed.
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Summary 
 
1. In higher eukaryotes, metabolism and immunity are tightly coupled. However, 
whereas evolutionary, a compromised immune response due to 
undernourishment has been the predominant problem, the inflammatory 
response to obesity and other life style-associated diseases gained in relevance 
in Western societies in the last hundred years. 
2. Traditionally, fat tissue has been considered as the major source of pro-
inflammatory secreted factors in these pathologies. In recent years however, the 
contribution of other tissues to a disease-causing chronic inflammation has been 
increasingly appreciated. 
3. The peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) is 
one of the key regulatory factors in the active skeletal muscle. Aberrant 
expression of PGC-1α in inactive muscle fibers could link a sedentary life style, 
persistent systemic inflammation and the higher risk for many chronic diseases. 
Modulation of PGC-1α activity in skeletal muscle might accordingly have a broad 
therapeutic effect. Here, recent advances in the understanding of the role of 
muscle PGC-1α in health and disease are reviewed. 
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Introduction 
 
Multicellular organisms depend on the ability to store energy for times of famine 
and to fight infections1, 2. The immune response is very energy demanding and 
therefore, inflammatory processes strongly inhibit anabolic processes such as 
those controlled by insulin signaling. For example, fever boosts energy 
consumption by 7-13% per 1°C increase in body temperature, sepsis even by 30-
60%3. On the other hand, an undernourished state is immunosuppressive, as 
observed malnourished or starving individuals with an increased susceptibility for 
infectious diseases. Accordingly, the molecular systems regulating metabolic 
processes and immune response have co-evolved and mutually regulate each 
other4. In lower organisms like the common fruit fly Drosophila melanogaster, 
metabolic and immune processes are even associated with one organ, the fat 
body, whereas in higher organisms, a deeper specialization of tissues occurred. 
Nevertheless, even in humans, metabolic organs are often closely linked with 
immune cells or have intrinsic immunomodulatory functions. For example, in the 
liver, hepatocytes are located adjacent to Kupffer cells, and macrophages are in 
close contact to adipocytes in fat1, 2, 4. 
 
In the past 100 years, physical activity and food intake patterns have changed 
drastically in Western countries. Concomitant with this shift in energy 
metabolism, the incidence rates for obesity, type 2 diabetes, cardiovascular 
disease, hypertension and other life style-associated pathologies have reached 
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epidemic proportions5, 6. Thus, in contrast to the previous 250’000 years when 
Homo sapiens mainly struggled with a lack of food, we now pay the price for an 
abundance of energy-rich food and the decreased importance of physical activity 
in daily life. Like malnutrition, overnutrition is linked to pathological changes in 
immune function, however in the diametrically opposite way. In contrast to the 
immunosuppression in undernourished individuals, the dysbalance between 
energy intake and dissipation triggered by overnutrition leads to a persistent, low-
grade inflammatory state and an increased susceptibility to chronic diseases2, 4. 
Importantly, this chronic inflammation is different from the classic immune 
response to an infectious agent and thus has been referred to as meta- or para-
inflammation2, 4. However, the same organs at the intersection of metabolism and 
immune function are involved in precipitating all of these different inflammatory 
responses7. 
 
Adipose tissue is a major driver of inflammation in obesity 
 
Excess energy is mostly stored in adipose tissue where adipocytes become 
enlarged, ultimately resulting in obesity. In addition to energy storage, fat is an 
important endocrine organ and accordingly secretes a number of hormones that 
regulate systemic energy homeostasis and appetite8-10. In an obese individual, 
adipocytes are also a major source of pro-inflammatory cytokines and other 
detrimental factors10, 11. Gökhan Hotamisligil, Bruce M. Spiegelman and 
colleagues described the production and secretion of the tumor necrosis factor α 
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(TNFα) by fat tissue in 1993 and thereby provided the first link between obesity, 
inflammation and insulin resistance12. In the meantime, numerous other adipose-
derived pro-inflammatory proteins, members of the “adipokine” family, have been 
identified11, 13. Once released, many of these hormones promote insulin 
resistance in other peripheral tissues. Thus, an inflammatory response from 
adipose tissue and to a lesser extent from the liver triggers early, disease-
causing events in obesity. 
 
Skeletal muscle as an endocrine organ 
 
Although an increased production of TNFα in skeletal muscle of obese patients 
has been reported in 199614, skeletal muscle as a significant contributor to 
chronic inflammation in metabolic diseases has been neglected for years. This is 
surprising since skeletal muscle makes up around 40% of body weight and is the 
largest storage site for glucose in the form of glycogen. Moreover, in a healthy 
organism, muscle tissue is very sensitive to insulin and the developing insulin 
resistance of this tissue contributes significantly to the etiology of type 2 
diabetes15, 16. Finally, a sedentary life-style is a strong and independent risk 
factor for many chronic diseases, including those that are associated with 
persistent, systemic inflammation17. For example, lack of adequate physical 
activity is linked to type 2 diabetes, obesity, cardiovascular diseases, certain 
cancers, neurodegeneration, musculoskeletal disorders and other pathologies, 
thereby increasing morbidity and mortality and reducing the quality of life as well 
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as overall life expectancy17. In contrast, exercise, even in the absence of 
significant weight loss, is an excellent preventative and therapeutic intervention 
for many chronic disorders18. For example, changes in life-style that consist of 
diet and exercise rival or even exceed currently prescribed drugs in terms of 
therapeutic efficacy against type 2 diabetes19. 
 
In recent years, factors produced and secreted by the contracting muscle fibers 
have been found and termed “myokines”, analogous to the adipokines that are 
released from fat20. Interestingly, many myokines have a complex expression 
pattern and exert beneficial and detrimental effects, respectively, depending on 
the cellular context20-22. For example, short-lived pulses of interleukin-6 (IL-6), IL-
8 and IL-15 are elicited by moderate exercise bouts and could mediate some of 
the systemic effects of physical activity (Fig. 1)23, 24. In contrast, persistent 
elevation of IL-6 is strongly associated with obesity and type 2 diabetes4. Thus, 
depending on the secretion pattern and the cellular context, IL-6 might mediate 
pro- or anti-inflammatory effects22. Very high-intensity exercise paradigms are 
accompanied with the elevation of a specific set of cytokines that includes IL-6 
and the unequivocally pro-inflammatory TNFα20, 25. In that context, these 
myokines most likely contribute to the immunocompromised and inflammatory 
state that is observed after extreme physical activity25. 
 
PGC-1α regulates muscle fiber plasticity 
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Exercise triggers major phenotypic adaptations in skeletal muscle. This biological 
program is predominantly regulated by changes in gene transcription26. 
Importantly, molecular changes in myofibers differ between the acute adaptations 
to individual bouts of exercise and those observed in a chronically trained 
muscle. In both cases however, similar signaling pathways are responsible for 
initiating the adaptations. Motor neuron activation of muscle fibers results in an 
elevation of intracellular calcium levels27-29. Increased energy metabolism and 
hence ATP consumption shifts the ATP to AMP ratio and thereby activates the 
AMP-dependent protein kinase (AMPK)30, 31. At the same time, an altered NAD+ 
to NADH ratio alters the activity of the silencing information regulator 2-ortholog 
SIRT132-34. The cellular stress associated with fiber contraction leads to an 
increased activity of the p38 mitogen-activated protein kinase (p38 MAPK) and 
the production of nitric oxide (NO)35, 36. Hormonal changes elicited by the fight-or-
flight reaction to physical activity include elevated levels of β-adrenergic agonists, 
some of which bind to β2-adrenoreceptors on the surface of muscle fibers26, 37. 
Finally, the exercise-induced synaptic remodeling of the neuromuscular junction 
(NMJ) are initiated and maintained by motor neuron-released paracrine factors 
that act on muscle38-40. Importantly, all of these signaling pathways converge on 
the peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) 
resulting in either a transcriptional induction, alteration of protein activity, or both 
(Fig. 2)41, 42. In turn, by binding to a diverse set of transcription factors, PGC-1α 
regulates many, if not all of the adaptations of the muscle fiber to endurance 
exercise41, 42. First and foremost, PGC-1α increases mitochondrial biogenesis 
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and function43. Accordingly, fatty acid β-oxidation, oxidative phosphorylation and 
ATP production are augmented44, 45. Then, the set of myofibrillar genes 
prototypical for the slow twitch, high endurance type I and IIa muscle fibers is 
induced by PGC-1α46. Furthermore, the expression of the ubiquitine ligases that 
promote protein degradation and fiber atrophy in an inactive muscle is reduced47. 
Finally, the transcriptional rate of genes encoding postsynaptic NMJ proteins is 
altered in synaptic nuclei38. Accordingly, ectopic expression of PGC-1α in 
skeletal muscle is sufficient to promote a fiber-type shift towards a higher 
proportion of oxidative muscle fibers and thereby evoke a trained phenotype in 
the mouse model46, 48. By inducing the biological program for exercise, elevation 
of PGC-1α even prevents disuse-induced fiber atrophy47, blunts the detrimental 
side-effects of statin drugs in muscle49, ameliorates Duchenne muscular 
dystrophy38 and a form of a mitochondrial myopathy50 in the respective animal 
models. 
 
Pathological consequences of PGC-1α dysregulation in muscle 
 
In humans, a tight correlation between the relative levels of physical activity and 
PGC-1α has been observed (e.g., ref 51). PGC-1α expression is transiently 
elevated after each bout of endurance exercise, similar to the expression pattern 
described for IL-6. In a chronically trained muscle, basal levels of PGC-1α are 
higher than those observed in an untrained individual51, yet a superimposed 
pulsative regulation of PGC-1α expression following each exercise bout is 
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maintained52. In contrast, aberrantly low PGC-1α levels are found in the muscle 
of sedentary individuals and type 2 diabetic patients, at least in some 
populations53, 54. It is unknown how much this dysregulation contributes to the 
etiology and pathology of this disease. However, a significant contribution of 
PGC-1α on glucose homeostasis is implied by the results from muscle-specific 
knockout mouse models. Mirroring the data from PGC-1α muscle transgenic 
mice46, PGC-1α muscle-specific knockout animals exhibit a higher number of 
glycolytic type IIx and IIb fibers concomitant with a reduction in mitochondrial 
gene expression and oxidative capacity55, 56. As a consequence, these mice are 
hypoactive and restricted in their ability to exercise55, 56. Moreover, whole body 
glucose and insulin homeostases are abnormally regulated56. These findings 
confirm the important role for PGC-1α in metabolic and myofibrillar plasticity of 
muscle fibers. Surprisingly though, PGC-1α muscle-specific knockout animals 
reveal signs of muscle damage as revealed by an increase in plasma creatine 
kinase levels and the number of perforated fibers in histological stainings55. 
Whereas this fiber damage is limited in sedentary animals, the myopathy is 
exacerbated by physical activity55. Thus, physiological levels of PGC-1α seem 
essential for normal muscle fiber integrity. 
 
Increased inflammation could link PGC-1α to muscle fiber damage 
 
It is unclear how fiber damage is triggered in muscle-specific PGC-1α knockout 
animals. Similarly, the molecular mechanisms that underlie the therapeutic 
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effects of PGC-1α in different muscle diseases are unknown, although several 
candidate mechanisms have been suggested57. Intriguingly, pro-inflammatory 
markers are elevated in mice with an ablated PGC-1α gene in muscle55, 56. In 
addition to the local inflammatory reaction in skeletal muscle, PGC-1α muscle-
specific knockout animals exhibit higher levels of circulating TNFα and IL-655, 56. 
Inflammation contributes to fiber damage and muscle wasting in a variety of 
different muscle diseases58-60. Whether the inflammation in PGC-1α muscle-
specific knockout mice is cause or consequence of the fiber damage has not 
been elucidated. For example, PGC-1α might directly modulate inflammatory 
gene expression, e.g., by altering reactive oxygen species in muscle, or the 
inflammation could be secondary to fiber damage and the subsequent removal of 
the debris. In any case however, the elevation of circulating pro-inflammatory 
factors and hence the systemic inflammatory state seems sufficient to link 
dysregulated muscle function to pathologies in other organs such as the deficient 
insulin secretion from pancreatic β cells in these animals56. 
 
Conclusions 
 
Chronic systemic inflammation is associated with an increased risk for many 
diseases. In addition, exercise has health benefits on the whole body, not just 
skeletal muscle. Thus, intrinsic adaptations in muscle fibers and the consequent 
distal signaling, most likely by hormonal or neuronal pathways, must mediate the 
crosstalk between active muscles and other organs. Reduction of PGC-1α levels 
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and the subsequent systemic elevation of pro-inflammatory cytokines might be 
the elusive link between a sedentary life-style and the increased risk for chronic 
diseases (Fig. 1)57. Accordingly, a pharmacological modulation of PGC-1α in 
muscle might have therapeutic benefits beyond that tissue. Unfortunately, 
despite various efforts, such compounds that robustly alter PGC-1α gene 
expression in skeletal muscle and not other tissues with potential detrimental 
side effects, and which can be safely and chronically used in patients remain 
elusive61, 62. Thus, as long as the inherent limitations of targeting a coactivator 
protein have not been overcome, a healthy life-style remains the best remedy 
against chronic diseases. 
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Figure Legends 
 
Fig. 1. Myokine production and the inflammatory state in skeletal muscle. 
Myokines secreted by an active muscle might contribute to the systemic 
beneficial effects of exercise. Reduced muscle activity is associated with 
impaired PGC-1α expression. A number of pro-inflammatory cytokines are 
elevated in individuals with inadequate physical activity. This persistent, low-
grade inflammation could subsequently increase the risk for a number of chronic 
diseases. In contrast, extreme performances and the accompanying fiber 
damage result in a state of temporary immunosuppression. 
 
Fig. 2. Regulation and function of PGC-1α in skeletal muscle fibers. All 
major signaling pathways that are activated in an active muscle fiber converge on 
the PGC-1α promoter, the protein or both. In turn, PGC-1α initiates the 
adaptations of muscle to physical activity by regulating metabolic, myofibrillar and 
neuromuscular junction-specific genes. 
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